Allogene Therapeutics, Inc.
ALLO
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The companā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.42
Price0.00%
$0.00
1Y
Price
Market Cap
$319.117m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-100.0%
1y CAGR-72.0%
3y CAGR-78.9%
5y CAGREarnings
-$212.015m
+17.7%
1y CAGR+14.3%
3y CAGR-11.0%
5y CAGREPS
-$0.98
+25.8%
1y CAGR+24.9%
3y CAGR-0.7%
5y CAGRBook Value
$315.329m
$439.771m
Assets$124.442m
Liabilities$85.142m
DebtDebt to Assets
19.4%
-0.4x
Debt to EBITDAFree Cash Flow
-$158.988m
+20.9%
1y CAGR+10.3%
3y CAGR+5.4%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company